Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.
PaperCitations, authors & open-access status
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 62 citations, 2020 year and closed oa status.
62
Citations
2020
Year
closed
OA Status